Psychosomatics 43:502-504, December 2002
© 2002 The Academy of Psychosomatic Medicine
Triptans
Scott C. Armstrong, M.D., and
Kelly L. Cozza, M.D.
Dr. Armstrong is the Co-Medical Director, Center for Geriatric Psychiatry, Tuality Forest Grove Hospital, Forest Grove, Ore., and Associate Professor of Psychiatry, Oregon Health Sciences University, Portland, Ore. Dr. Cozza is the staff psychiatrist for the Infectious Disease Service, Department of Medicine, Walter Reed Army Medical Center, Washington, DC, and Assistant Professor of Psychiatry, Uniformed Services University of the Health Sciences, Bethesda, Md. Address correspondence to Dr. Armstrong, Tuality Forest Grove Hospital, 1809 Maple St., Forest Grove, OR 97116; scott.armstrong{at}tuality.org (e-mail).The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.
ABSTRACT
Triptans are potent serotonin (5-HT) 1B/1D receptor agonists used to abort and treat migraine headaches. Although the triptans share pharmacodynamic characteristics at 5-HT1B/1D receptors, they differ pharmacokinetically. This coulmn reviews how the triptans are metabolized. Generally, the triptans are metabolized by phase I monoamine oxidases (MAOs) and by various cytochrome P450 enzymes. However, each triptan has a unique metabolic profile, leading to significant differences in each triptan's potential for drug-drug interactions. These differences are detailed in this review.
Key Words: Drug-Drug Interactions
Get information about faster international access.
Privacy Policy
Copyright © 2002
Academy of Psychosomatic Medicine.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
